Zacks Research Has Weak Outlook for Henry Schein Q3 Earnings

Henry Schein, Inc. (NASDAQ:HSIC) – Research analysts at Zacks Research dropped their Q3 2026 earnings per share (EPS) estimates for Henry Schein in a research report issued on Monday, August 24th. Zacks Research analyst Team now expects that the company will post earnings per share of $1.33 for the quarter, down from their prior forecast of $1.38. The consensus estimate for Henry Schein’s current full-year earnings is $5.35 per share. Zacks Research also issued estimates for Henry Schein’s Q4 2026 earnings at $1.40 EPS, FY2026 earnings at $5.32 EPS, Q1 2027 earnings at $1.38 EPS, Q2 2027 earnings at $1.39 EPS, FY2027 earnings at $5.82 EPS, Q1 2028 earnings at $1.57 EPS, Q2 2028 earnings at $1.56 EPS and FY2028 earnings at $6.32 EPS.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.24 by $0.03. The firm had revenue of $3.46 billion during the quarter, compared to analyst estimates of $3.37 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The business’s revenue was up 6.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS.

Other equities research analysts have also recently issued reports about the stock. Stifel Nicolaus set a $95.00 price objective on shares of Henry Schein in a research report on Wednesday, August 5th. UBS Group set a $94.00 target price on shares of Henry Schein and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Wall Street Zen raised shares of Henry Schein from a “hold” rating to a “buy” rating in a research note on Monday, August 17th. Barclays reiterated an “overweight” rating and issued a $100.00 price target (up from $86.00) on shares of Henry Schein in a report on Thursday, August 6th. Finally, Barrington Research set a $104.00 price objective on Henry Schein in a research note on Wednesday, August 5th. Nine research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $92.93.

Henry Schein Trading Up 1.1%

HSIC stock opened at $89.51 on Tuesday. Henry Schein has a 12 month low of $61.94 and a 12 month high of $92.18. The firm’s 50-day moving average is $85.91 and its 200 day moving average is $79.66. The company has a market capitalization of $9.98 billion, a PE ratio of 26.10, a P/E/G ratio of 1.69 and a beta of 0.80. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.32 and a quick ratio of 0.73.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System lifted its position in shares of Henry Schein by 7,452.4% in the 2nd quarter. California State Teachers Retirement System now owns 9,364,429 shares of the company’s stock worth $782,117,000 after purchasing an additional 9,240,437 shares during the period. Ameriprise Financial Inc. boosted its stake in shares of Henry Schein by 3,275.2% during the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after purchasing an additional 2,199,695 shares in the last quarter. Bank of Montreal Can increased its holdings in Henry Schein by 3,655.7% during the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after buying an additional 2,087,666 shares during the period. Norges Bank purchased a new position in Henry Schein during the fourth quarter valued at approximately $88,116,000. Finally, Southpoint Capital Advisors LP raised its stake in Henry Schein by 28.0% in the first quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock worth $235,840,000 after buying an additional 700,000 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.